ITM-91 by ITM Isotope Technologies Munich for Pancreatic Ductal Adenocarcinoma: Likelihood of Approval

ITM-91 is under clinical development by ITM Isotope Technologies Munich and currently in Phase II for Pancreatic Ductal Adenocarcinoma.

RNA Therapeutics Core launches at Mass General Brigham to boost circular RNA research

The Mass General Brigham Gene and Cell Therapy Institute (GCTI) today announced it has launched the RNA Therapeutics Core, a first-of-its-kind, state-of-the-art facility and resource

September 3, 2024

Could vitamin D be the missing link in managing type 2 diabetes? Recent study weighs in

Vitamin D’s role in type 2 diabetes management is evolving, with evidence suggesting it may improve blood sugar levels and reduce diabetes-related inflammation.

October 29, 2024

The GLP-1 Agonist Plateau No One’s Talking About

The declines in body weight that patients experience with injectables like semaglutide (Ozempic, Wegovy) and tirzepatide (Mounjaro) are no exception to the concept that nothing

September 23, 2023

Supercharge Your Portfolio with Future Health Stocks!

Join us for Profitable Insights & Expert Tips!

With expert analysis, comprehensive market coverage, and actionable insights, our newsletter equips you with the knowledge & tools necessary to make informed decisions & maximize your potential returns in the dynamic world of future health stocks.